Pfizer Inc. (NYSE:PFE)’s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses, but promised to keep key research jobs in Britain as part of its $106 billion takeover bid. Pfizer Inc. (NYSE:PFE) stock performance was 0.24% in last session and finished the day at $29.20. Traded volume was 26.29million shares in the last session and the average volume of the stock remained 30.44million shares. The beta of the stock remained 0.73. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Merck & Co. Inc. (NYSE:MRK) will receive at least $600 million in a deal with Japanese drugmaker Santen Pharmaceutical Co. for the purchase of Merck & Co. Inc. (NYSE:MRK) eye care products in several markets. The Whitehouse Station, N.J., drugmaker said the deal was another step in its push to sharpen its commercial focus. Merck & Co. Inc. (NYSE:MRK) also recently announced that it had agreed to sell its consumer health business to Germany’s Bayer AG for $14.2 billion. That includes Claritin allergy pills, Coppertone sun-care line, and Dr. Scholl’s foot-care products. Merck & Co., Inc. (NYSE:MRK) rose 0.83 percent to $55.75 Tuesday on volume of 8.96million shares. The intra-day range of the stock was $55.20 to $56.06. Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $163.94Billion.

Gilead Sciences Inc. (NASDAQ:GILD) said a Phase 2 study showed that an investigational combination of ranolazine and low-dose dronedarone reduced atrial fibrillation burden. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on May 13, 2014 reported a decrease of -0.06% to the closing price of $80.30. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $123.32billion. The overall volume in the last trading session was 8.51million shares. In its share capital, GILD has 1.54billion outstanding shares.

MannKind Corporation (NASDAQ:MNKD) reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, total operating expenses were $41.4 million, compared to $36.4 million for the first quarter of 2013, an increase of $5.0 million. The net loss applicable to common stockholders for the first quarter of 2014 was $52.1 million, or $0.14 per share based on 368.8 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $41.0 million, or $0.15 per share based on 280.1 million weighted average shares outstanding for the first quarter of 2013. On Tuesday, shares of MannKind Corporation (NASDAQ:MNKD) advanced 3.95% to close the day at $6.58. Company monthly performance is recorded as 2.65%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 15.64%.